Top Markets
Coin of the day
Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

RVX
Rangering i aksjer #28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Aksjekurs
$0.07339369
Sist synkronisert: 2026-08-18
Markedsverdi
$25.24M
Endring (1 dag)
5.26%
Endring (1 år)
-9.55%
Land
CA
Handel Resverlogix Corp. (RVX)

Kategori

EPS for Resverlogix Corp. (RVX)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Resverlogix Corp. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Resverlogix Corp. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$-7.98 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH